Stocks to Watch Today, 10th March 2025: Reliance Infrastructure, Tata Power, Gensol Engineering, VI, and more

Indian share markets set to open lower despite mixed trading session across Asian bourses. The GIFT Nifty was down 46 points at 22,604 at 7:30 AM IST, signalling a negative start for the markets. The muted mood was a result of investors watching US President Donald Trump's tariffs and the wider ramifications of a global trade war. Further complicating the international economic picture is China’s recent announcement that it will retaliate with tariffs on some Canadian agricultural goods, following Ottawa’s decision to impose import duties on Chinese-made electric vehicles, steel and aluminium.

Key Stocks in Focus

Reliance Infrastructure: Board of Directors have approval a Scheme of arrangement. The scheme involves the merger of its wholly-owned subsidiary, Reliance Velocity Limited (RVL), with the company and their respective shareholders.

Tata Power: Incorporated under the Companies Act of 2013, Tata Power Renewable Energy is a wholly owned subsidiary of Tata Power. The agreement plans to explore potential renewable energy development opportunities in the state that could achieve up to 7,000 MW (7 GW) of capacity. These projects can include solar, wind, and hybrid projects with or without energy storage systems and are expected to attract investments of nearly ₹49,000 crore.

Vodafone Idea: Income-tax Department issues a penalty order of ₹10.79 crore against Vodafone Idea According to the order, the firm did not provide information is required and didn't document inter-company transactions relatively to transfer pricing rules for the Assessment Year 2020-21. Vodafone Idea plans to challenge this directive.

Lupin: Lupin has received final approval from the USFDA for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 2.5 mg and has launched it on 8 October 2023. This drug is approved to decrease the risk of major adverse cardiovascular events in individuals with CAD and had projected annual sales of $446 million in the US.

Biocon Biologics: A subsidiary of Biocon Ltd, has announced positive results from a pivotal Phase 3 trial of its PsO drug in adult patients with moderate to severe chronic plaque psoriasis (PsO), the company said Monday.

HFCL: Material subsidiary of the HFCL i.e., HTL Limited has received a domestic order of ` 44.36 crore for supply Tactical Optical Fiber Cable Assemblies from the Indian Army to be executed by July 2025.

Gensol Engineering: Promoters have sold around 2.37 per cent of the company's total  equity shares or 9 lakh shares. The move is meant to free up liquidity for an equity infusion to reinvest in the business. It will also consider a stock split and a proposal for raising funds at its March 13, 2025, meeting.

GR Infraprojects: The board of directors at G R Infraprojects has approved the divestment of the entire equity stake it holds in its wholly-owned subsidiary, GR Galgalia Bahadurganj Highway Private Limited. In other news, the Board has declared an interim dividend of ₹12.50 per equity share for the Financial Year 2024-25.

Nazara Technologies: The company has completed the sale of its 94.85 per cent stake in OpenPlay Technologies Private Limited, the parent company of classic Rummy platform game Classic Rummy, to Moonshine Technology Private Limited, the parent company of PokerBaazi. The consideration for the transaction is ₹104.33 crore, which will be paid via issuance of Moonshine's Compulsory Convertible Preference Shares (CCPS) to Nazara and other sellers.

Bhagyanagar India: The company has entered into an agreement with Crescentia Technology Private Limited to acquire a 51 per cent stake with a purpose for Trading, Distribution, Supply, Generation, Transmission and Manufacturing of solar energy-related products.

Narayana Hrudayalaya: Health City Cayman Islands Ltd. (HCCI), a 99 indoor/1 outdoor wholly owned overseas subsidiary of Narayana Hrudayalaya, has entered into a Joint Venture Agreement with 2070 Health Inc., W Health Ventures GP LLC, and Everhope Oncology Private Limited. The target is to set up and run the network of healthcare centres in India for treatment of cancer patients.

Oriental Rail Infrastructure: The company said it has received its first order in the 'Vande Bharat' segment from Rail Coach Factory (RCF), Kapurthala, Indian Railways, worth ₹42.89 crore.

CDSCO: Government of India, has approved AstraZeneca Pharma India to import Durvalumab solution for infusion. This allows the company to market and distribute Durvalumab in patients with limited-stage small cell lung cancer (LS-SCLC).

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here.